A Call to Action: Monoclonal Antibodies for the Prevention and Treatment of COVID-19

CLINICAL RESOURCE CENTER

Use the QR Code or URL to access the program slides, accreditation and disclosure information, as well as the clinical resource center.

www.ExchangeCME.com/COVIDMAb This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from AstraZeneca.

This is an affiliated event (not official IDWeek programming).

LIVE FACULTY

“CALL-A-COLLEAGUE” FACULTY

Eric S. Daar, MD

Lucy Horton, MD, MPH

Chief, Division of HIV Medicine Harbor-UCLA (University of California, Los Angeles) Medical Center Investigator, Lundquist Institute Professor of Medicine David Geffen School of Medicine at UCLA Torrance, California

Associate Professor of Medicine Infectious Disease Specialist UC San Diego Health San Diego, California

Raymund R. Razonable, MD, FIDSA, FAST

Vice Chair, Organ Transplant Surgery Director, Organ Transplantation Professor of Surgery and Medicine Zucker School of Medicine at Hofstra Northwell Health New York, New York

Professor of Medicine Program Director, Infectious Diseases Fellowship Program Vice Chair, Division of Infectious Diseases Mayo Clinic College of Medicine and Science Rochester, Minnesota

Phyllis Tien, MD Professor of Medicine, Division of Infectious Diseases University of California (UC), San Francisco Staff Physician San Francisco Veterans Affairs Health Care System San Francisco, California

Lewis Teperman, MD, FACS

Charles P. Vega, MD, FAAFP Clinical Professor, Family Medicine Director, UC Irvine Program in Medical Education for the Latino Community Associate Dean, School of Medicine University of California, Irvine Irvine, California

TARGET AUDIENCE

Physician Accreditation Statement

This program is intended to educate infectious disease, internal medicine, and other clinicians involved in the management of patients who are at heightened risk for poor outcomes for coronavirus disease 2019 (COVID-19).

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

PROGRAM DESCRIPTION Multiple anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) have gained Emergency Use Authorization (EUA) from the US Food and Drug Administration for both treatment and prevention of COVID-19, though the presence of multiple new variants and subvariants has rapidly shifted mAb efficacy and EUA status. Clinicians struggle to remain up to date with a rapidly changing field that has remained a public health concern. A panel of experts will present data on and discuss current evidence and regulatory status for these anti-SARS-CoV-2 mAbs and available antivirals, updates to National Institutes of Health guidelines on patient identification and stratification for both treatment and prevention, implementation through COVID-19 clinic models, and strategies to reduce health care disparities. The panel will utilize additional experts to augment discussion and provide expertise on multiple topics.

Physician Credit Designation

EDUCATIONAL OBJECTIVES

Global Education Group designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-108-L01-P) This is a knowledge- based activity.

After completing this activity, participants will be better prepared to: • Describe the clinical profiles, trial data, and regulatory status for anti-SARS-CoV-2 mAbs for preexposure prophylaxis and treatment • Identify candidates for preexposure prophylaxis or treatment with anti-SARS-CoV-2 mAbs, including immunocompromised patients • Collaborate with patients and other clinicians to overcome barriers to the use of antiSARS-CoV-2 mAbs for preexposure prophylaxis or treatment

PROGRAM AGENDA

Global Education Group designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Nurse Practitioner Continuing Education This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and (name of other entity). Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education.

Provider number: 110121. This activity is approved for 2.0 contact hour(s) (which includes 0.1 hour(s) of pharmacology).

6:00–6:10 pm

Preactivity Questionnaire and Faculty Introductions

6:10–6:30 pm

An Overview of COVID-19 and Anti-SARS-CoV-2 Monoclonal Antibodies

6:30–6:55 pm

Best Practices for Preexposure Prophylaxis

Global Contact Information

6:55–7:25 pm

Considerations for COVID-19 Treatment

7:25–7:45 pm

Disparities in the Use of Anti-SARS-CoV-2 Monoclonal Antibodies

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

7:45–8:00 pm

Postactivity Questionnaire and Q&A Session

Instructions to Receive Credit

Disclosure of Unlabeled Use

Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest with a 70% or better and submit the evaluation form directly after the activity. Pharmacist learners must check the CPE monitor within 30 days of the activity for their credit.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Fee Information& Refund/Cancellation Policy There is no fee for this educational activity.

Disclosures of Conflicts of Interest Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies: Eric S. Daar, MD

Consultant Fees: Gilead, Merck; Contracted Research: Gilead, ViiV

Lucy Horton, MD

Consulting Fees: Gilead, GSK

Raymund R. Razonable, MD

Contracted Research: Gilead (funds to institution), Roche, Regeneron; Honoraria: Member of DSMB for Novartis

Lewis Teperman, MD

Nothing to disclose

Phyllis Tien, MD

Contracted Research: Gilead, Merck

Charles P. Vega, MD

Consulting fees: GlaxoSmithKline plc., Johnson & Johnson

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.